# WeCareLife Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wecarelife-biotech-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Latest round: Series A (Jan 19, 2026)
- Investors on record: 1

## About

Based in Beijing, China, and founded in 2021, WeCareLife Biotech Co., Ltd. is a biotechnology company that focuses on developing drug delivery platforms.

In January 2026, WeCareLife Biotech Co., Ltd. raised an undisclosed amount of series A funding from returning investor Heda Capital.

The company has developed the Adiposome-based Drug Delivery System which adopts nanotechnology and can be used in the fields of small molecule innovative drugs, and large molecule innovative drugs such as antibodies, peptides, nucleic acids, etc. The adiposome-based drug delivery technology has advantages in fat solubility, targeting, scalability, etc.

The company expects to complete the IND (Investigational New Drug) filing of several improved small molecules, complete the validation of the drugability of 1-2 FIC (First in Class) small molecules, and carry out preclinical studies by the end of 2025.

## Funding rounds

- Series A, Jan 19, 2026 — Heda Capital

## Investors

- Heda Capital (https://capitalatlas.ai/funds/heda-capital) — Series A